Investors have circled back to healthcare stocks this year, and they’re likely to stick around. If they came for the ...

GRAIL faces financial challenges but holds significant growth potential with its Galleri cancer-screening test. Click here to ...

2 Since then, aside from the Illumina/Grail transaction, the Commission called in a small number of concentrations. The ...

The Rome Study demonstrated the value of extensive sequencing and discussion of individual cancer cases to offer tailored therapeutic choices.

ANGLE ANNOUNCES NEXT GENERATION SEQUENCING ASSAY AGREEMENT WITH NUPROBE Option for exclusive licence to highly sensitive NGS ...